SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim’s Antifungal Webinar

SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim’s Antifungal Webinar

GlobeNewswire

Published

JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer, will participate in a fireside chat at H.C. Wainwright’s 22^nd Annual Global Investment Healthcare Conference taking place September 14-16, 2020. Dr. Taglietti will also partake in a panel discussion at Maxim’s antifungal webinar taking place September 17, 2020.*Presentation details:*

*H.C. Wainwright 22^nd Annual Global Investment Conference*
Presentation Date: Tuesday, September 15, 2020
Presentation Time: 2:30 p.m. ET
Webcast: 
https://wsw.com/webcast/hcw7/register.aspx?conf=hcw7&page=scyx&url=https://wsw.com/webcast/hcw7/scyx
 
*Maxim’s Antifungal Webinar *
Webinar Topic: A Too Quiet Pandemic – Fungal Disease
Date: Thursday, September 17, 2020
Time: 11:00 a.m. ET
Register to attend via link

A webcast of the HCW presentation and a recording of the Maxim webinar will be available for 30 days on the SCYNEXIS website at: https://www.scynexis.com/news-media/events

*About SCYNEXIS*

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

*CONTACT**: *
*Investor Relations
*Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

*Media Relations
*Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

Full Article